Hematology-Oncology
Kim, Won Seog
95 AppointmentProfessor of Hematology and Oncology, Sungkyunkwan University School of Medicine
Speciality Interests
Schedule
12 | FRI 01 |
MON 04 |
TUE 05 |
WEN 06 |
THU 07 |
---|---|---|---|---|---|
AM | available | ||||
PM | available |
Medical School
Ph.D. in Medicine College of Medicine, Seoul National University Master of Science College of Medicine, Seoul National University
Specialty Training
Fellowship | 1996~1997 Fellowship Section of Medical Oncology, Dept. of Internal Medicine, Samsung Medical Center. Seoul, Korea 1995~1996 Fellowship Section of Medical Oncology, Dept. of Internal Medicine, Seoul National University Hospital |
|
---|---|---|
Residency | 1991~1995 Residency Dept. of Internal Medicine, Seoul National University Hospital | |
Internship | 1990~1991 Internship Seoul National University Hospital |
Other Education
2010~present Professor Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center,Sungkyunkwan University, School of Medicine Seoul, Korea
2004~2010 Associate Professor Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center,Sungkyunkwan University, School of Medicine Seoul, Korea
2000~2004 Assistant Professor Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center,Sungkyunkwan University, School of Medicine Seoul, Korea
1998~2000 Full-time lecturer Division of Hematology-Oncology, Dept. of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea
1997~1998 Staff Division of Hematology-Oncology, Dept. of Medicine, Samsung Medical Center, Seoul, Korea
Participation in Academic Societies
and Research
Member Korean Medical Association
Member Korean Association of Internal Medicine
Member Korean Society of Hematology
Chairman lymphoma working party of Korean society of hematology
Chairman Consortium of improving survival of lymphoma ( CISL)
Founding member Asian lymphoma study group ( ALSG)
Co-Chair T cell lymphoma forum (TCLF)
Thesis
BLOOD ADV 2021 10.1182/bloodadvances.2020004074
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
LANCET HAEMATOL 2021
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
ANTIVIR RES 2021 10.1016/j.antiviral.2021.105063
Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications
CANCER MANAG RES 2021 10.2147/CMAR.S309092
Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
KOREAN J INTERN MED 2021 10.3904/kjim.2019.367
Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia